Transpharmation Ltd. Expands Its Horizons with OrganoTherapeutics Acquisition

In an exciting development for the field of neuroscience, Transpharmation Ltd., a leading global provider focusing on contract preclinical research, has announced the strategic acquisition of OrganoTherapeutics SARL, a pioneering company in patient-derived organoid technologies. This acquisition marks a significant step forward in the quest to accelerate the discovery and development of new treatments for neurodegenerative disorders affecting the central nervous system (CNS).

With rising complexities surrounding neurodegenerative diseases such as Alzheimer’s and Parkinson's, recent advancements in genetics, biomarkers, patient-derived cell models, and translational neuroscience have ushered researchers into a transformative era. Dr. Mark Duxon, CEO of Transpharmation Ltd., expressed excitement about the acquisition, stating, "Transpharmation has built a reputation in translational in vivo pharmacology over the past 25 years. By acquiring OrganoTherapeutics, we take a significant step towards our ambition of establishing clinical research services (CRO) focused on translational research involving human tissues and systems. We foresee a promising future for our company in delivering non-animal models, complementing our preclinical pharmacology efforts. Assuring better predictions of drug action and efficacy before clinical trials is critical, especially in the neurological space, where patient-derived 3D organoids will enhance our clients' confidence in their drug candidates."

OrganoTherapeutics will continue to operate as a subsidiary under the Transpharmation banner, allowing for smooth transitions and collaborative synergies to strengthen both organizations' strengths. Co-founder Dr. Jens Schwamborn also expressed optimism regarding this union, emphasizing the value of working together to leverage their established expertise in pharmacology and neural models. He highlighted that, over recent years, OrganoTherapeutics has developed human iPSC-derived organoid and assembloid models targeted at studying diseases such as Parkinson’s, Huntington’s, and ALS.

As the combined forces of Transpharmation and OrganoTherapeutics unfold, they will strategically channel their expertise in translational neuroscience and patient-derived organoid technology. This collaboration aims to support biopharmaceutical developers in studying disease biology, validating therapeutic targets, and evaluating new treatments using advanced human-relevant models and established translational research frameworks. By integrating these approaches, Transpharmation hopes to provide a more predictive path from research to development, thus facilitating innovation in neurodegenerative disease research.

Advancements in the development of patient-relevant predictive systems are fueling a rapid pace of research. The therapeutic landscape in neurobiology is evolving, and researchers have access to a broad pool of knowledge, enhancing their capabilities when equipped with a comprehensive expert team.

About Organoids Derived from Human Stem Cells

Brain organoids are miniature brain tissue models cultivated from stem cells sourced from healthy volunteers or patients. These organoids incorporate various key brain cell types, allowing scientists to explore brain diseases like Parkinson’s using authentic human cells and more efficiently test promising new treatments before entering clinical trials.

OrganoTherapeutics, based in Luxembourg, focuses on organoid and assembloid models of the midbrain, specifically for neurodegenerative diseases, developed from proprietary research. The firm collaborates with pharmaceutical and biotechnology partners to deliver models that reflect critical disease characteristics, such as dopaminergic neuron vulnerability in Parkinson’s, thereby enhancing research output.

Relevance of Human-Relevant Models in Neurodegenerative Disease Research

Neurodegenerative diseases like Alzheimer’s and ALS gradually damage nerve cells in the brain and spinal cord, with limited treatments available to slow progression. Traditional research models can often fail to accurately represent human conditions, leading to gaps in understanding. These human-relevant models help bridge that gap; utilizing brain organoids derived from stem cells—often from the patient’s own cells—allows researchers thorough investigations of diseases in living human tissues.

Combining organoid models with established preclinical approaches offers scientists a clearer picture of how potential treatments might behave in humans, aiding in better decision-making, reducing costly late-stage failures, and ultimately accelerating the delivery of effective therapies to patients.

Insights on Transpharmation

Transpharmation is a scientist-led contract research organization well-known for transforming lives through its focus on drug discovery and development. Our clients benefit from decades of experience in cross-species translational biology across various therapeutic domains, especially with preclinical assessments focused on CNS disorders including epilepsy, pain management, neurodegeneration, depression, anxiety, schizophrenia, and cognitive impairments.